RSV Challenge Model For Anti-RSV Therapy

Respiratory syncytial virus (RSV) is a common virus that causes respiratory tract infections, particularly in infants and older adults, leading to severe conditions like bronchiolitis. Despite symptoms resembling the common cold or flu, RSV can result in significant morbidity and hospitalizations. Currently, no vaccine is available, though palivizumab, a monoclonal antibody, is used to prevent severe RSV symptoms in high-risk infants. As pharmaceutical and biotechnology companies work to develop effective RSV vaccines, the need for reliable rodent models to study the disease and test potential treatments is critical.

Aragen has developed such models for preclinical testing of drugs, including anti-RSV antibodies, small molecules, and vaccines, supporting research in infectious diseases and other areas. This case study highlights a non-GLP study conducted by Aragen to evaluate the efficacy of a sponsor-developed antibody using RSV challenge mouse models.